{"type":"trials","record":{"id":42025,"source_id":"clinicaltrials-gov","external_id":"NCT05390840","title":"A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)","brief_summary":"A 2 parts Phase II study to investigate the effect on central macular thickness of treatment with MG-O-1002 eye drops in participants aged over 45 with neovascular age-related macular degeneration (nAMD)","overall_status":"Unknown","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Theratocular Biotek Co.","enrollment":36,"countries":["Thailand"],"start_date":"2022-08-09","completion_date":"2024-03-01","last_update_date":"2024-03-13","source_url":"https://clinicaltrials.gov/study/NCT05390840","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"45 Years","comparator":"Part 2 (MG-O-1002 or Placebo)","organization":"Metagone Biotech Inc.","interventions":["MG-O-1002","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean change from baseline in central macular thickness over 12 weeks. — up to 12 weeks","Mean change from baseline in Best-Corrected Visual Acuity over 12 weeks — up to 12 weeks","Mean Change from baseline in Visual Field over 12 weeks — up to 12 weeks","Mean change from baseline in total area of Choroidal Neovascularization (CNV) over 12 weeks — up to 12 weeks","The number of patients needing rescue treatment within 12 weeks — up to 12 weeks","The time to rescue treatment for needed patients within 12 weeks — up to 12 weeks","Incidence and severity of ocular and systemic adverse events — up to 12 weeks"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · SINGLE","source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration","MG-O-1002","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05390840","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-08-09 to 2024-03-01","comparator":"Part 2 (MG-O-1002 or Placebo)","confidence":"structured-source","population":"ALL · 45 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.909Z","intervention":["MG-O-1002","Placebo"],"participants":36,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · SINGLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean change from baseline in central macular thickness over 12 weeks. — up to 12 weeks","Mean change from baseline in Best-Corrected Visual Acuity over 12 weeks — up to 12 weeks","Mean Change from baseline in Visual Field over 12 weeks — up to 12 weeks","Mean change from baseline in total area of Choroidal Neovascularization (CNV) over 12 weeks — up to 12 weeks","The number of patients needing rescue treatment within 12 weeks — up to 12 weeks","The time to rescue treatment for needed patients within 12 weeks — up to 12 weeks","Incidence and severity of ocular and systemic adverse events — up to 12 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42025","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}